ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Disc Medicine, Inc. due to allegations of materially misleading business information issued to the investing public [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased Disc Medicine securities may be entitled to compensation through a contingency fee arrangement, with no out-of-pocket costs [2]. - A class action is being prepared by Rosen Law Firm to seek recovery of investor losses [2]. Group 2: Regulatory Issues - On February 13, 2026, the FDA issued a Complete Response Letter to Disc Medicine regarding its bitopertin program, stating that the new drug application could not be approved due to uncertainties requiring additional evidence [3]. - Following the FDA's announcement, Disc Medicine's stock price experienced a significant decline of 22% on the same day [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked highly for the number of settlements since 2013 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].